Pharma BD Deal Intelligence
Astex Pharmaceuticals (an Otsuka company) announced on July 6, 2026 an exclusive, worldwide research collaboration and license agreement with Genentech (a member of the Roche Group) to develop small-molecule inhibitors of a key cell-cycle-dependent regulator as potential breast-cancer therapies. Astex receives USD 25 million upfront and is eligible for preclinical, clinical, regulatory and sales milestones totaling more than USD 490 million, plus tiered royalties. Astex grants Genentech an exclusive license to compounds from its existing breast-cancer discovery program (originating from work with Newcastle University and Cancer Research Horizons); Genentech takes sole responsibility for preclinical/clinical development and global commercialization. NOTE: ingested at pending_review pending a fourth independent source.